Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 20 of 157 for:    eribulin

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02404506
Recruitment Status : Active, not recruiting
First Posted : March 31, 2015
Last Update Posted : March 1, 2019
Sponsor:
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research

Brief Summary:

Breast cancer is the most frequent malignancy in women, world-wide the leading cause of cancer mortality. One of the strongest risk factors for developing breast cancer is age, with a prevalence approaching 7% in women >70 years; more than 40% of breast cancer patients are older than 65 years. Although the survival rate has increased in the last years, about one third of patients will relapse with distant metastases. Treatment for patients with metastatic breast cancer is palliative, therefore maintaining or improving quality of life.

The use of taxanes and anthracyclines as first line chemotherapy regimen for metastatic breast cancer is widely accepted. Both taxanes and anthracyclines have considerable side effects, especially in elderly patients.

Eribulin, a synthetic analogue of a chemotherapeutically active compound derived from the sea sponge Halichondria okadai, acts as an inhibitor of microtubule dynamics. It is registered as palliative chemotherapy in advanced breast cancer after anthracyclines and taxanes. Studies with eribulin treatment have shown similar efficacy compared to anthracyclines and taxanes, but less toxicity. Those studies showed that often the dose of eribulin had to be reduced during treatment due to toxicity without compromising the efficacy of the treatment.

The main objective of the trial is to explore the efficacy of a reduced starting dose of eribulin as first-line treatment in elderly metastatic breast cancer patients. The secondary objective of the trial is to investigate the safety of eribulin in those patients.

Eribulin mesilate 1.1mg/m2 i.v. will be administered intravenously every 3 weeks on day 1 and day 8 until progressive disease.


Condition or disease Intervention/treatment Phase
Breast Cancer Adenocarcinoma Drug: Eribulin mesilate Phase 2

Detailed Description:

Due to a rising number of elderly patients, fit for chemotherapy, investigating a well-tolerated and effective first line treatment is warranted. In this specific population often there are contra-indications for the use of standard first line drugs like anthracyclines and taxanes due to comorbidities (e.g. cardiac impairment or Peripheral neuropathy). Response rates in first line treatment with taxanes and anthracyclines usually do not exceed 30%. Eribulin has shown a response rate of 29% and a clinical benefit rate (corresponding to the investigators primary endpoint) of 52% in first line, so the investigators expect similar efficacy, but less toxicity.

Optimal dose, schedule and tolerability of this drug in the first line setting are unknown in the elderly population. No information on dose modifications in this population is available. Based on the data of eribulin in the first line with higher efficacy in those patients with dose reductions, the SAKK 25/14 trial investigates the reduced starting-dose of eribulin of 1.1mg/m2 for this vulnerable population of elderly patients. Growth factors to maintain a certain dose level of eribulin are not recommended, respecting the international guidelines.

SAKK has a tradition in conducting trials in the elderly population, such as SAKK 25/99 in metastatic breast cancer, SAKK 38/08 in aggressive B-cell-Lymphoma, SAKK 41/10 in metastatic colorectal cancer.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 77 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Eribulin as 1st Line Treatment in Elderly Patients (≥ 70 Years) With Advanced Breast Cancer: a Multicenter Phase II Trial
Actual Study Start Date : August 17, 2015
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : October 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Arm: Eribulin mesilate Drug: Eribulin mesilate
Eribulin mesiylate 1.1mg/m2 d1, 8 every 3 weeks until Progressive disease PD
Other Name: Halaven




Primary Outcome Measures :
  1. Disease Control (DC) [ Time Frame: 24 weeks ]
    A patient has DC, if she has complete response (CR) or partial response (PR) at any time point during treatment, or if she has stable disease (SD) for at least 24 weeks (according to RECIST v1.1).


Secondary Outcome Measures :
  1. Time to treatment failure (TTF) [ Time Frame: at treatment discontinuation (at the latest 5 years after registration) ]
    time from registration until treatment discontinuation due to any reason or the occurrence of a second tumor. Patients still on treatment will be censored at the date of their last eribulin administration

  2. Objective response (OR) [ Time Frame: at treatment discontinuation (at the latest 5 years after registration) ]

    A patient is defined as having OR, if she has CR or PR according to RECIST v1.1 at any time point during treatment.

    For the primary analysis, all responses (CR, PR) will be considered, including unconfirmed responses. In a sensitivity analysis, only those responses for which a confirmatory measurement at least 4 weeks later is available will be counted as CR or PR


  3. Time to progression (TTP) [ Time Frame: at time of progression, death or treatment discontinuation (at the latest 5 years after registration) ]

    TTP is defined as time from registration until documented progression according to RECIST v1.1 or death due to tumor.

    Patients not experiencing an event and patients starting a new anticancer therapy in the absence of an event will be censored at the date of their last available tumor assessment showing non-progression.


  4. Overall survival (OS) [ Time Frame: at time of death (at the latest 5 years after registration) ]
    OS is defined as time from registration until death from any cause. Patients not experiencing an event will be censored at the last date they were known to be alive.

  5. Adverse events (AEs) [ Time Frame: until 30 days after last dose of treatment and resolution of all related AEs thereafter (at the latest 5 years after registration) ]
    AEs will be assessed according to NCI CTCAE v4.0.

  6. Patient reported neuropathy (PRO Form) and characterization of patients based on cancer-specific geriatric assessment (C-SGA) [ Time Frame: at the first follow-up visit (at the latest 5 years after registration) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   70 Years and older   (Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient must give written informed consent according to ICH/GCP regulations before registration
  • Histologically or cytologically confirmed locally advanced or metastatic HER2-neg, hormone receptor positive or negative adenocarcinoma of the breast with measurable or evaluable disease according to RECIST 1.1 criteria
  • At least 6 months since last adjuvant/neoadjuvant chemotherapy administration before registration
  • At least 2 weeks since prior radiotherapy or endocrine therapy and complete recovery from these interventions at time of registration
  • Baseline C-SGA and patient-reported outcome (PRO) forms have been completed
  • Female patient at the age of ≥70 years
  • WHO performance status 0-2
  • Adequate hematological values: hemoglobin ≥80 g/L (transfusions are allowed), neutrophils ≥1.5 x 109/L, platelets ≥ 100 x 109/L
  • Adequate hepatic function: bilirubin ≤1.5 x ULN, AST ≤3 x ULN, alkaline phosphatase (AP) ≤2.5 x ULN (in case of liver metastases ≤5 x ULN or in case of bone metastases ≤10 x ULN)
  • Adequate renal function (calculated creatinine clearance >40 mL/min, according to the formula of Cockcroft-Gault)

Exclusion Criteria:

  • Known CNS metastases
  • Previous malignancy within 3 years with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer
  • Prior chemotherapy for advanced disease
  • Concurrent anticancer treatment or treatment in a clinical trial within 30 days prior to registration. Exception: participation in SAKK 96/12
  • Palliative irradiation prior to study entry with more than 30% of marrow-bearing bone irradiated
  • Pre-existing neuropathy ≥G2 (according to CTCAE v4.0) at registration
  • Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV (see Appendix 4), unstable angina pectoris, history of myocardial infarction within the last three months, significant arrhythmias, congenital long QT-syndrome)
  • Any concomitant drugs contraindicated for use with the trial drugs according to the approved product information
  • Known hypersensitivity to trial drug or to any component of the trial drug
  • Any serious underlying medical condition (at the judgment of the investigator) which could impair the ability of the patient to participate in the trial (e.g. active autoimmune disease, uncontrolled diabetes)
  • Psychiatric disorder precluding understanding of trial information, giving informed consent, taking part in the geriatric assessment, or interfering with compliance/with the trial protocol
  • Any familial, sociological or geographical condition potentially hampering proper staging and compliance with the trial protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02404506


Locations
Layout table for location information
Switzerland
Kantonsspital Aarau
Aarau, Switzerland, CH-5001
Kantonsspital Baden
Baden, Switzerland, 5404
Universitaetsspital-Basel
Basel, Switzerland, 4031
Praxis für ambulante Tumortherapie
Basel, Switzerland, CH-4052
Istituto Oncologico della Svizzera Italiana
Bellinzona, Switzerland, 6500
Klinik Engeried / Oncocare
Bern, Switzerland, 3012
Inselspital, Bern
Bern, Switzerland, CH-3010
Spitalzentrum Biel
Biel, Switzerland, CH-2501
Kantonsspital Graubünden
Chur, Switzerland, 7000
Kantonsspital Frauenfeld / Brustzentrum Thurgau
Frauenfeld, Switzerland, 8501
HFR Fribourg - Hôpital cantonal
Fribourg, Switzerland, 1708
Clinique de Genolier
Genolier, Switzerland, CH-1272
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland, CH-1011
Clinica Sant'Anna - Oncologia Varini & Calderoni & Christinat
Lugano, Switzerland, 6900
Kantonsspital Luzern
Luzerne, Switzerland, CH-6000
Onkologie Zentrum Spital Männedorf
Männedorf, Switzerland, 8708
Kantonsspital Olten
Olten, Switzerland, 4600
Rundum Onkologie am Bahnhofpark
Sargans, Switzerland, 7320
Onkologiezentrum Bürgerspital Solothurn
Solothurn, Switzerland, CH-4500
Onkologiepraxis Dr. med. Isabella Schönenberger
St. Gallen, Switzerland, 9000
Tumorzentrum ZeTUP
St. Gallen, Switzerland, 9006
Kantonsspital - St. Gallen
St. Gallen, Switzerland, CH-9007
Regionalspital
Thun, Switzerland, 3600
Kantonsspital Winterthur
Winterthur, Switzerland, 8401
Onkozentrum - Klinik im Park
Zurich, Switzerland, 8002
Brust-Zentrum AG Zürich
Zürich, Switzerland, 8005
Sponsors and Collaborators
Swiss Group for Clinical Cancer Research
Investigators
Layout table for investigator information
Study Chair: Ursula Hasler-Strub, MD Cantonal Hospital of St. Gallen

Layout table for additonal information
Responsible Party: Swiss Group for Clinical Cancer Research
ClinicalTrials.gov Identifier: NCT02404506     History of Changes
Other Study ID Numbers: SAKK 25/14
000001310 ( Other Identifier: SNCTP )
First Posted: March 31, 2015    Key Record Dates
Last Update Posted: March 1, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Swiss Group for Clinical Cancer Research:
Eribulin
Breast Cancer
Elderly Patient
Phase II Trial
HER2-neg
adenocarcinoma

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Adenocarcinoma
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type